Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Boule Diagnostics AB's 3-Year RORE % for the quarter that ended in Mar. 2026 was 9.75%.
The industry rank for Boule Diagnostics AB's 3-Year RORE % or its related term are showing as below:
CHIX:BOULs's 3-Year RORE % is ranked better than 64.61% of 777
companies
in the Medical Devices & Instruments industry
Industry Median: -4.03
vs CHIX:BOULs: 9.75
Boule Diagnostics AB (CHIX:BOULs) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Boule Diagnostics AB 3-Year RORE % Related Terms
Boule Diagnostics AB 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BOULS vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Boule Diagnostics AB (CHIX:BOULS) has a 3-Year RORE % of 9.75 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Boule Diagnostics AB and its competitors. According to the industry distribution chart, Boule Diagnostics AB ranks #275 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 35.4%.
Is Boule Diagnostics AB's 3-Year RORE % too high?
Boule Diagnostics AB's current 3-Year RORE % is 9.75. Based on the distribution chart, Boule Diagnostics AB ranks #275 out of 777 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #275 out of 777 companies for 3-Year RORE %. This puts Boule Diagnostics AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Boule Diagnostics AB and its competitors. Boule Diagnostics AB's current 3-Year RORE % is 9.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current 3-Year RORE % of 9.75. The stock's GF Value™ is kr49.42, compared to a current price of kr26.30 — trading 46.8% below its estimated fair value. The current 3-Year RORE % is 9.75. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current 3-Year RORE % is 9.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 46.8% below its estimated GF Value™ of kr49.42.
Key valuation signals for CHIX:BOULS:
3-Year RORE %: 9.75
GF Value™: kr49.42 vs. price of kr26.30 (46.8% below fair value)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for CHIX:BOULS
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
